Top Story Today
Lilly's Retatrutide Posts Record-Shattering Weight Loss, Then Misses the Number That Actually Matters
Retatrutide just delivered 28.3% average weight loss at the highest dose, numbers that rival bariatric surgery and top every obesity drug ever tested. But here's the catch: the triple-agonist failed to show a statistically significant reduction in heart attacks, strokes, or cardiovascular deaths. In an era where insurers increasingly demand hard cardiovascular outcomes before covering expensive obesity drugs, that gap could limit retatrutide to a premium, restricted tier while semaglutide (with its proven heart benefits) claims the broadest coverage. Lilly has a dedicated cardiovascular outcomes trial running, but results won't arrive until 2028 or 2029.
Why it matters: The result exposes a new reality in obesity medicine: losing weight isn't enough anymore. Payers and regulators now expect these drugs to prevent heart attacks too, which could reshape how every future obesity therapy is valued, priced, and covered.
Read more →Deals and M&A
AbbVie Bets $10.9 Billion on a Company That Didn't Exist in 2022
AbbVie is paying $135.11 per share (a roughly 49% premium) to acquire Apogee Therapeutics, a clinical-stage biotech founded in 2022 with zero approved drugs. The prize: zumilokibart, an anti-IL-13 antibody that could challenge Dupixent with dosing every three to six months instead of every two weeks. The deal won't be accretive until 2032, but AbbVie needs the next generation of immunology blockbusters as Humira's biosimilar erosion continues.
Read more →Novartis Drops $1.1 Billion on a Preclinical ADC Platform With a Brand-New Warhead
Novartis is acquiring London-based Myricx Bio and its novel NMT-inhibitor ADC payload for $1.1 billion upfront ($1.5 billion total). No clinical data exists yet. The bet: a completely new mechanism for killing cancer cells that sidesteps the resistance problems plaguing existing ADC payloads. Roughly 90% of preclinical drugs never reach approval, making this one of pharma's priciest early-stage gambles.
Read more →Clinical Setbacks
The Heart Drug That Aced Every Test, Then Bombed the Final
AstraZeneca and Ionis's eplontersen failed the largest ATTR cardiomyopathy trial ever run (1,432 patients, 20 countries), despite proven success in nerve disease. The culprit: 57% of patients were already on stabilizer therapy, and the drug added zero benefit on top of it. Ionis shares fell over 20%. The real winners are Alnylam and BridgeBio, whose competing drugs now face one fewer rival in a fast-growing ATTR cardiomyopathy market.
Read more →Pfizer's $43 Billion Seagen Bet Loses a Crown Jewel
Sigvotatug vedotin, an ADC inherited from Pfizer's blockbuster Seagen acquisition, failed to improve overall survival in a pivotal lung cancer trial of 703 patients. The drug couldn't beat decades-old chemotherapy. HSBC downgraded Pfizer and cut the drug's approval probability to 40%. The Seagen thesis isn't dead (PADCEV still looks strong), but the margin for error on a $43 billion bet just got uncomfortably thin.
Read more →Sarepta's Gene Therapy Gets a Black Box Warning; 500 Jobs Cut in the Same Week
After two patient deaths from acute liver failure, the FDA slapped its most severe safety warning on Sarepta's Duchenne gene therapy Elevidys and barred non-ambulatory patients from receiving it. Revenue collapsed from $375 million in Q1 2025 to $110 million by Q4. With the stock down 80%, $1 billion in debt, and a third of its workforce gone, Sarepta is pivoting away from the gene therapy platform it was built on.
Read more →Regulatory and Science Milestones
CRISPR Gene Therapy Cleared for Toddlers for the First Time Ever
The FDA approved Vertex's Casgevy for sickle cell patients as young as two, a world first for CRISPR in children this small. In trials, every treated child remained free of painful crises during follow-up. The decision used extrapolation (no direct data in the youngest kids), creating a regulatory template for how future gene-editing therapies could reach pediatric patients faster.
Read more →The FDA Built a Regulatory Highway for One-Patient Gene Therapies
A new FDA framework lets gene therapies designed for as few as one patient reach approval without traditional large-scale trials. The key: a "Plausible Mechanism Framework" that accepts biomarkers and mechanistic evidence instead. The science is exciting, but the economics are terrifying. When your patient population fits in a minivan, there are no economies of scale to absorb costs that already start at $1 million per dose.
Read more →CAR-T Therapy Cracks the Solid Tumor Wall for the First Time
China approved the world's first CAR-T for a solid tumor: CARsgen's satri-cel for advanced stomach cancer. The therapy roughly doubled progression-free survival versus standard care. The results are modest compared to CAR-T's dramatic blood cancer remissions, but after a decade of failed attempts, any solid-tumor approval rewrites what the field thought was possible.
Read more →A Drug Finally Cleared the Survival Bar in Small Cell Lung Cancer
GSK and Hansoh's ADC ris-rez hit a statistically significant overall survival benefit in relapsed small cell lung cancer, a disease that has defeated nearly every new therapy for decades. It's the first positive phase III survival result for a B7-H3 ADC in any cancer. Full numbers are pending, but in a disease where the median survival bar hasn't budged in years, clearing it at all is noteworthy.
Read more →